NAD+ Supplements: What Human Research Shows About Oral NAD+

Quick answer. NAD+ (nicotinamide adenine dinucleotide) is a coenzyme that every cell uses, and it is sold as capsules and powders. We found only one published randomized trial of NAD+ taken by mouth: it tested a proprietary, modified powder for five days and measured blood levels, not health outcomes. Animal research and the NIH Office of Dietary Supplements indicate that NAD+ in food is broken down to nicotinamide, a form of vitamin B3, before it is absorbed, and most human research quoted about "NAD+ supplements" actually tested related compounds such as NR and NMN. That five-day trial reported one case of mild nausea, but there are no long-term safety studies of oral NAD+.

What NAD+ is

NAD+ is a coenzyme that more than 400 enzymes need. The body makes it from niacin (nicotinic acid and nicotinamide) and, in part, from the amino acid tryptophan (NIH ODS). NAD+ and its reduced partner, NADH, carry electrons in the reactions cells use to make energy (Zhu 2015), and NAD+ is used up by signaling enzymes such as PARPs and sirtuins (Liu 2018). Some foods contain small amounts of NAD and NADP, which, according to NIH ODS, "are converted to nicotinamide in the gut and then absorbed."

Three kinds of products are often confused, and research on one does not apply to the others:

• NAD+ itself, sold as capsules or powder.
• NADH, the reduced form, also sold as a dietary supplement (Rainer 2000).
• Precursors the body converts into NAD+: nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), nicotinamide and nicotinic acid.

What human studies have tested

The first three rows are the main peer-reviewed studies we found that gave NAD+ itself to healthy adults or wellness clients. A 2026 review of IV NAD+ describes a few other small, uncontrolled reports (Alangari 2026), and NAD+ has also been given by IV as a hospital drug. The other rows test precursors and are included for comparison, because they are often cited as if they were NAD+ research.

What the findings suggest

Is swallowed NAD+ absorbed intact? Probably not. In a rat study using labeled NAD, intestinal enzymes split NAD into smaller pieces, and nicotinamide "was the major if not the only labeled compound absorbed" (Gross 1983). NIH ODS describes the same fate for NAD in food. The 2026 human trial fits this picture: NAD rose in blood cells but not in plasma. The authors list, as "a plausible alternative explanation," that orally administered NAD+ "is substantially hydrolyzed prior to absorption," acting mainly as a source of nicotinamide, and say their study "cannot determine contributions among these mechanisms." The animal data and official summaries agree, but direct human absorption data are lacking.

Broken down is not the same as wasted. NIH ODS states that all tissues convert absorbed niacin, which includes nicotinamide, into NAD. The open question is whether oral NAD+ does anything that the same amount of nicotinamide would not. No trial has compared them.

What blood NAD+ numbers mean. Whole-blood tests mainly reflect NAD+ inside blood cells; plasma, the liquid part of blood, carries very little (Kornilov 2026). Average whole-blood values in healthy adults ranged from about 18 to 29 µM across studies (Balashova 2022; Breton 2020; Kornilov 2026). Labs use different methods, and NAD+ is unstable in blood samples unless handled carefully (Liang 2014, a mouse methods study), so results from different tests are not directly comparable. In precursor trials, consistent rises in NAD markers came with mixed and often null effects on outcomes (Gallagher 2026), so a higher number does not by itself show a benefit.

IV vs oral. An IV puts NAD+ straight into the blood, yet plasma NAD+ was "rapidly and completely removed" for the first two hours of infusion (Grant 2019). IV NAD+ has also been tested as a hospital drug, for example 10 mg/day for 7 days in 180 adults with heart failure in China (Yu 2026). That is a different use, dose and route.

"NAD+ declines with age" is a measurement, not proof that supplements help. Lower NAD+ in older people has been reported in skin (Massudi 2012), plasma (Clement 2019), brain scans (Zhu 2015) and muscle (Janssens 2022). Blood studies disagree. In 151 healthy blood donors aged 19 to 68, whole-blood NAD was not correlated with age overall (Breton 2020). Two 2026 studies using validated assays also found whole-blood NAD+ stable across adult ages: one pooled seven independent cohorts (Trętowicz 2026), the other covered healthy adults aged 18 to 70 (Euro 2026; three of its six authors list a company affiliation). A 2025 review found that a decline has been "consistently observed only in a limited number of studies" (Vinten 2025). Raising blood levels with precursors has not reliably changed outcomes (Gallagher 2026).

Where the evidence is limited or conflicting

• One published oral NAD+ trial. It lasted five days, used a proprietary modified powder with no plain-NAD+ comparison, and was registered retrospectively, more than three years after it ended (ClinicalTrials.gov NCT07336836). The authors also did not disclose how the powder differs from ordinary NAD+: their analyses of the formulation are "not disclosed due to proprietary considerations."
• More trials are registered than published. On ClinicalTrials.gov, a 4-week placebo-controlled trial of NAD+ tablets in 53 women aged 40 to 80, with cognitive tests and blood markers as main outcomes, was listed as completed in February 2026; we found no posted or published results (NCT06579209). An 8-week trial in 80 adults had not started recruiting (NCT07692633).
• No published outcome trials of plain NAD+ capsules. We found no published trial of ordinary oral NAD+ with energy, fatigue, sleep, cognition or aging markers as main outcomes.
• NADH is a different molecule. The NADH trials cited here used 10–20 mg a day, with mixed results. In chronic fatigue syndrome, one small crossover trial found more responders with NADH than placebo (Forsyth 1999), while another found no change in most measures (Alegre 2010). In dementia, two small studies disagree (Demarin 2004; Rainer 2000).
• Precursor results do not transfer. We found no published head-to-head trial of oral NAD+ against NR or NMN.

What buyers say, and what the research shows

Our team read 2,025 public Amazon reviews of eight NAD+ and nicotinamide riboside (NR) products, including Vinatura's own listing, collected in September 2026. Reviews show what buyers believe or report; they cannot show whether a product caused any change. We checked the most common beliefs against the studies.

Belief: oral NAD+ isn't absorbed, so NR or NMN is the better choice. On the two single-ingredient NAD+ products from other brands, 25 critical reviews said oral NAD+ isn't absorbed. The first half is partly supported: NAD+ appears to be broken down in the gut, mainly to nicotinamide. The second half is not established. NR and NMN have more trials showing that blood NAD rises, but their health effects are mixed, and no trial has compared them with oral NAD+.

Belief: NAD+ capsules do nothing. "It did nothing" made up at least 10% of critical reviews (weighted toward reviews other buyers found helpful) on every product in the sample. That fits the research: no wellbeing measure held up in the oral NAD+ trial, and precursor trials often found no effect on functional outcomes.

Belief: NAD+ capsules increase energy. More energy was the most common, or joint most common, reason for buying in every product group. No published trial of oral NAD+ has measured energy or fatigue as a main outcome, and a 2026 meta-analysis found that no precursor significantly improved perceived fatigue (Gao 2026). A rise in blood NAD is not the same as feeling more energetic.

Belief: capsules are a cheaper substitute for IV NAD+. A small share of reviews (under 3% in every product group) describe moving from IV or injection clinics to capsules. The routes deliver NAD+ differently, so results cannot be swapped, and IV NAD+ has very little evidence for healthy adults.

Safety

• Oral NAD+. In the five-day trial, one person taking NAD+ had mild nausea, and symptom rates were similar to placebo. We found no longer studies.
• IV NAD+. No adverse events were observed during a slow six-hour infusion of 750 mg in eight men (Grant 2019), but all six clients given 500 mg at rates they set themselves had moderate to severe symptoms that stopped when the infusion ended (Reyna 2026). A 2024 randomized pilot, posted as a preprint and not peer-reviewed, also found more and stronger infusion symptoms with 500 mg of IV NAD+ than with IV NR; its corresponding author works for the company that makes the NR product tested (Hawkins 2024).
• The nicotinamide link. Each NAD+ molecule carries one nicotinamide unit. If swallowed NAD+ were fully broken down, each gram would release at most about 184 mg of nicotinamide (our calculation from molecular weights). Neither NIH ODS nor EFSA sets an upper limit for NAD+ or says that the niacin limits apply to it. The U.S. adult limit of 35 mg/day for supplemental niacin (nicotinic acid and nicotinamide) is based on skin flushing, which comes from nicotinic acid; nicotinamide itself does not cause flushing, and the limit does not apply under medical supervision (NIH ODS). The more relevant comparison is the limit the EU Scientific Committee on Food set for nicotinamide itself: 900 mg/day for adults, with none set for pregnancy or breastfeeding because data were inadequate (EFSA). NIH ODS notes nausea, vomiting and signs of liver toxicity with nicotinamide at 3,000 mg/day.
• Pregnancy, breastfeeding, children and medicines. We found no safety data for oral NAD+ in these groups and no interaction studies with medicines. Follow your product label, and ask a pharmacist or doctor first if you take prescription medicines or have a medical condition.

What research does not establish

• That swallowed NAD+ reaches the body's cells intact.
• That oral NAD+ improves energy, sleep, memory, aging or any health outcome.
• That oral NAD+ works better or worse than NR, NMN or nicotinamide.
• That a higher blood NAD+ number means better health.
• That oral or IV NAD+ is safe for long-term use.

How we reviewed the evidence

We searched PubMed on October 24–25, 2026 for human studies of oral and intravenous NAD+, NADH trials, NAD+ and aging, blood NAD+ measurement, comparisons with NR or NMN, and reviews of NAD+ precursors. We screened more than 200 records and read full texts where we report numbers not given in an abstract. On October 25 we also searched ClinicalTrials.gov for registered NAD+ trials and their results, and read one IV NAD+ preprint, labeled here as not peer-reviewed. We read the NIH Office of Dietary Supplements niacin fact sheet and EFSA's overview of upper intake levels. We kept NAD+, NADH and precursor studies apart, separated human from animal and lab studies, and noted funding and author ties where disclosed. Buyer beliefs come from our team's internal analysis of public Amazon reviews collected in September 2026. Vinatura did not run its own trials.

Vinatura Research Perspective

We asked four questions of every study: which molecule was tested (NAD+, NADH or a precursor), by which route, at what dose, and whether it measured blood levels or something people would notice. Read this way, the evidence shrinks quickly. Much of what is cited online as "NAD+ research" concerns NR, NMN or IV infusions. The only published randomized trial of swallowed NAD+ used a proprietary modified powder at 2,000 mg a day for five days, was sponsored by the powder's maker, and measured blood levels rather than outcomes.

We also did a simple calculation: fully broken down, each gram of NAD+ would yield at most about 184 mg of nicotinamide. If the gut handles NAD+ the way it handles NAD in food, a dose may act largely as a nicotinamide source, which would make nicotinamide, not NR or NMN, the fairest comparison. No study has tested that. Our assessment: evidence that oral NAD+ raises blood NAD is limited; evidence for any energy or health outcome is insufficient; short-term safety data are limited and long-term data are missing. An independent, placebo-controlled trial of plain oral NAD+ for at least 8–12 weeks, with a nicotinamide arm matched for nicotinamide content, standardized whole-blood and plasma assays, prespecified fatigue or function outcomes and fully published methods, would change this assessment.

Where this ingredient appears in Vinatura products

NAD+ Supplement 1000MG provides 1,000 mg of NAD (nicotinamide adenine dinucleotide) per 2-capsule serving. The studies above did not test this product.

Frequently asked questions

Is NAD+ the same as NADH? No. NADH is the reduced form of the same coenzyme. The NADH trials cited here used 10–20 mg a day, and their results do not apply to NAD+ supplements.

Can a blood test show whether NAD+ is working? It shows a level at one point in time. Results depend on whether the test measures whole blood or plasma and on the lab method, and no level has been linked to a health outcome.

Is IV NAD+ stronger than capsules? It skips digestion, but it has very little evidence for healthy adults. In a small clinic review, all six people given IV NAD+ at rates they chose themselves had symptoms such as nausea and chest pressure; a slow six-hour infusion in eight men produced no observed adverse events.

References

• Kornilov SA, et al. Oral LNAD+ rapidly elevates whole blood intracellular NAD and metabolic flux without elevating plasma NAD: evidence from a randomized controlled trial. GeroScience. 2026. doi:10.1007/s11357-026-02399-1
• Grant R, et al. A pilot study investigating changes in the human plasma and urine NAD+ metabolome during a 6 hour intravenous infusion of NAD+. Front Aging Neurosci. 2019;11:257. doi:10.3389/fnagi.2019.00257
• Reyna K, et al. Intravenous infusion of nicotinamide adenine dinucleotide (NAD) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting. Front Aging. 2026;7:1652582. doi:10.3389/fragi.2026.1652582
• Alangari A, et al. Narrative review of intravenous NAD+ and NAD+ precursors in wellness and translational medicine. Front Aging. 2026;7:1887175. doi:10.3389/fragi.2026.1887175
• Hawkins J, et al. Randomized, placebo-controlled, pilot clinical study evaluating acute Niagen+ IV and NAD+ IV in healthy adults. medRxiv [preprint, not peer-reviewed]. 2024. doi:10.1101/2024.06.06.24308565
• Okabe K, et al. Oral administration of nicotinamide mononucleotide is safe and efficiently increases blood nicotinamide adenine dinucleotide levels in healthy subjects. Front Nutr. 2022;9:868640. doi:10.3389/fnut.2022.868640
• Dollerup OL, et al. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. Am J Clin Nutr. 2018;108(2):343–353. doi:10.1093/ajcn/nqy132
• Gallagher C, et al. NAD⁺ supplementation for anti-aging and wellness: a PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Res Rev. 2026;116:103057. doi:10.1016/j.arr.2026.103057
• Gao Y, et al. Domain-specific effects of NAD precursors on fatigue and functional performance: a systematic review and network meta-analysis. Front Nutr. 2026;13:1890335. doi:10.3389/fnut.2026.1890335
• Gross CJ, Henderson LM. Digestion and absorption of NAD by the small intestine of the rat. J Nutr. 1983;113(2):412–420. doi:10.1093/jn/113.2.412
• Liu L, et al. Quantitative analysis of NAD synthesis-breakdown fluxes. Cell Metab. 2018;27(5):1067–1080.e5. doi:10.1016/j.cmet.2018.03.018
• Zhu XH, et al. In vivo NAD assay reveals the intracellular NAD contents and redox state in healthy human brain and their age dependences. Proc Natl Acad Sci USA. 2015;112(9):2876–2881. doi:10.1073/pnas.1417921112
• Massudi H, et al. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS One. 2012;7(7):e42357. doi:10.1371/journal.pone.0042357
• Clement J, et al. The plasma NAD+ metabolome is dysregulated in "normal" aging. Rejuvenation Res. 2019;22(2):121–130. doi:10.1089/rej.2018.2077
• Janssens GE, et al. Healthy aging and muscle function are positively associated with NAD+ abundance in humans. Nat Aging. 2022;2(3):254–263. doi:10.1038/s43587-022-00174-3
• Breton M, et al. Blood NAD levels are reduced in very old patients hospitalized for heart failure. Exp Gerontol. 2020;139:111051. doi:10.1016/j.exger.2020.111051
• Trętowicz MM, et al. Human whole-blood NAD+ levels do not vary with age or lifestyle interventions. Nat Metab. 2026;8(6):1282–1290. doi:10.1038/s42255-026-01537-5
• Euro L, et al. Dynamics of blood NAD and glutathione in health, disease, aging, and under NAD-booster treatment. Redox Biol. 2026;96:104343. doi:10.1016/j.redox.2026.104343
• Vinten KT, et al. NAD+ precursor supplementation in human ageing: clinical evidence and challenges. Nat Metab. 2025;7(10):1974–1990. doi:10.1038/s42255-025-01387-7
• Balashova NV, et al. Efficient assay and marker significance of NAD+ in human blood. Front Med (Lausanne). 2022;9:886485. doi:10.3389/fmed.2022.886485
• Liang X, et al. Measuring NAD(+) levels in mouse blood and tissue samples via a surrogate matrix approach using LC-MS/MS. Bioanalysis. 2014;6(11):1445–1457. doi:10.4155/bio.14.8
• Yu X, et al. Effect of nicotinamide adenine dinucleotide on heart failure caused by ischemic cardiomyopathy: a randomized, placebo-controlled trial. Am J Cardiovasc Drugs. 2026;26(1):97–106 (published online 2025). doi:10.1007/s40256-025-00764-7
• Forsyth LM, et al. Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome. Ann Allergy Asthma Immunol. 1999;82(2):185–191. doi:10.1016/S1081-1206(10)62595-1
• Alegre J, et al. Nicotinamide adenine dinucleotide (NADH) in patients with chronic fatigue syndrome [in Spanish]. Rev Clin Esp. 2010;210(6):284–288. doi:10.1016/j.rce.2009.09.015
• Demarin V, et al. Treatment of Alzheimer's disease with stabilized oral nicotinamide adenine dinucleotide: a randomized, double-blind study. Drugs Exp Clin Res. 2004;30(1):27–33. PubMed 15134388
• Rainer M, et al. No evidence for cognitive improvement from oral nicotinamide adenine dinucleotide (NADH) in dementia. J Neural Transm (Vienna). 2000;107(12):1475–1481. doi:10.1007/s007020070011
• National Institutes of Health, Office of Dietary Supplements. Niacin: Fact Sheet for Health Professionals. Updated November 18, 2022. ods.od.nih.gov
• European Food Safety Authority. Overview on Tolerable Upper Intake Levels as derived by the Scientific Committee on Food (SCF) and the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Version 11, August 2025. efsa.europa.eu
• ClinicalTrials.gov. NCT07336836: Characterization of the effects of oral NAD+ in a wellness cohort (RENEWAL-NAD+). Record read October 25, 2026. clinicaltrials.gov
• ClinicalTrials.gov. NCT06579209: NAD+ oral supplement pilot intervention in adult females. Record read October 25, 2026. clinicaltrials.gov
• ClinicalTrials.gov. NCT07692633: A clinical trial to assess the absorption, safety, and efficacy of an oral NAD+ supplement in healthy adults. Record read October 25, 2026. clinicaltrials.gov

Editorial note: This article reviews published research for educational purposes. It does not establish the effects or safety of any specific supplement, including Vinatura products, and is not medical advice. Written by Vinatura Editorial Team. Last reviewed October 2026.